1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Astrazeneca plc - ADR

Pascal Soriot

1 Francis Crick Avenue
Cambridge, Cambridgeshire CB2 0AA
Phone: 11442073045000


AstraZeneca: What The Market''s Missing
Apr 24, 2024 08:30am

AstraZeneca has a strong pipeline, recent approvals, and a series of acquisitions that offer promising prospects. Read why AZN stock is a Buy.

Source:Seeking Alpha
ANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection
Apr 24, 2024 07:24am

LONDON (dpa-AFX) - ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE''s existing DNA damage response or ''DD…

Source:Finanz Nachrichten
Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca
Apr 24, 2024 07:16am

No summary available.

Source:Seeking Alpha
ANGLE plc (ANPCY: OTCQX International) | Angle PLC Announces New Commercial Agreement with AstraZeneca
Apr 24, 2024 06:02am

No summary available.

Source:OTC Markets
Angle PLC Announces New Commercial Agreement with AstraZeneca
Apr 24, 2024 06:00am

ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative … Jetzt den vollständigen Artikel lesen

AstraZeneca CEOs 1.8mn pay rise approved despite shareholder opposition
Apr 23, 2024 15:53pm

AstraZeneca hiked its dividend to persuade shareholders to accept CEO Pascal Soriots pay rise. Is he worth his salary?

Insights Into Astrazeneca Q1: Wall Street Projections for Key Metrics
Apr 22, 2024 21:31pm

In its upcoming report, Astrazeneca (NYSE: AZN ) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $11.94 billion, representing a year-over-year increase of 9.7%. Over the last 30 days, there has been a downward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts'' collective reconsideration of their initial forecasts over the course of this timeframe. Ahead of a company''s earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to …

3 Blue-Chip Stocks to Buy as High Inflation Persists
Apr 19, 2024 10:10am

Inflation in the United States has been stubborn and a matter of concern for policymakers. For March, the consumer price increase rose by 3.5% on a year-on-year basis, which was more than expected. That dashed hopes of an interest rate cut relatively soon. If GDP growth disappoints, concerns related to a potential hard landing will increase. From an investment perspective, the scenario calls for exposure to blue-chip stocks for inflation and possible market volatility. An important point to note is that rate cuts can potentially boost GDP growth. At the same time, easy money policies are positive for the markets. Therefore, if rate cuts continue to be delayed, there will likely be a correction. That strengthens the case for investing in low-beta blue-chip stocks. I must, however, add that I believe the first-rate cut will likely be before the presidential election. Therefore, any correction of 5% or 10% would be a good opportunity to accumulate quality stocks. For now, let’s discuss three blue-chip stocks for inflation.

AstraZeneca''s IMFINZI Plus Chemotherapy Reduces Death Risk By 26% At 3 Yrs. In TOPAZ-1 Phase 3 Study
Apr 16, 2024 11:54am

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) Tuesday announced follow-up data for TOPAZ-1 Phase III trial showing IMFINZI plus chemotherapy demonstrated clinically meaningful long-term overall survi…

Source:Finanz Nachrichten
Sunday papers: Trouble at Tesla? The headache facing Elon Musk
Apr 14, 2024 06:12am

And L%26G fires warning shot at AstraZeneca over Pascal Soriot pay.